{
    "symbol": "AGIO",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-05 11:24:13",
    "content": " We have better clarity with respect to the launch trajectory as we walkaways will be for the quarters based on our work to date, we continue to believe that approximately 1500 to 4000 consider efficiency patients in the U.S. representing a peak revenue potential in the U.S. of $200 million to $225 million via a dose passionate commercial organization with significant rare disease experience that is fully capable of executing our launch strategy and be excited and grateful for the impact making one the lives of the PK deficiency patients."
}